Dr. Hamilton on How Neratinib Targets HER2+ Breast Cancer

Erika P. Hamilton, MD
Published: Sunday, Oct 08, 2017



Erika P. Hamilton, MD, director of the Breast and Gynecologic Research Program at Sarah Cannon Research Institute, discusses how neratinib (Nerlynx) targets HER2-positive breast cancer.

Following 1 year of trastuzumab (Herceptin), patients enrolled on a clinical trial received neratinib, an oral tyrosine kinase inhibitor that blocks HER2, or placebo during another 1 year of trastuzumab, Hamilton says. This trial resulted in neratinib's FDA approval, as there was a small, but meaningful improvement (< 2%) in women who did not have their disease recur during that time.

Neratinib has been shown to have a lesser benefit in patients who have a lower risk of recurrence, she says. Another safety concern is that patients may also experience diarrhea despite taking antidiarrheal medication.


Erika P. Hamilton, MD, director of the Breast and Gynecologic Research Program at Sarah Cannon Research Institute, discusses how neratinib (Nerlynx) targets HER2-positive breast cancer.

Following 1 year of trastuzumab (Herceptin), patients enrolled on a clinical trial received neratinib, an oral tyrosine kinase inhibitor that blocks HER2, or placebo during another 1 year of trastuzumab, Hamilton says. This trial resulted in neratinib's FDA approval, as there was a small, but meaningful improvement (< 2%) in women who did not have their disease recur during that time.

Neratinib has been shown to have a lesser benefit in patients who have a lower risk of recurrence, she says. Another safety concern is that patients may also experience diarrhea despite taking antidiarrheal medication.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 16th Annual International Congress on the Future of Breast Cancer®Sep 29, 20182.0
School of Breast Oncology®: Mid-Year Video Update OnlineSep 30, 20182.0
Publication Bottom Border
Border Publication
x